Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Moreau, P. (Philippe); Chari, A. (Ajai); Oriol, A. (Albert); Martínez-López, J. (Joaquín); Haenel, M. (Mathias); Touzeau, C. (Cyrille); Ailawadhi, S. (Sikander); Besemer, B. (Britta); Rubia-Comos, J. (Javier) de la; Encinas, C. (Cristina); Mateos, M.V. (María Victoria); Salwender, H. (Hans); Rodriguez-Otero, P. (Paula); Hulin, C. (Cyrille); Karlin, L. (Lionel); Sureda-Balari, A. (Anna); Bargay, J. (Joan); Benboubker, L. (Lotfi); Rosiñol, L. (Laura); Tarantolo, S. (Stefano); Terebelo, H. (Howard); Yang, S. (Shiyi); Wang, J. (Jianping); Nnane, I. (Ivo); Qi, M. (Ming); Kosh, M. (Michele); Delioukina, M. (Maria); Goldschmidt, H. (Hartmut)

Keywords:

Daratumumab
Multiple myeloma
Lenalidomide-refractory

Issue Date:

2023

Publisher Version:

https://pubmed.ncbi.nlm.nih.gov/36882409/

ISSN:

2044-5385

Note:

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http:// creativecommons.org/licenses/by/4.0/.

URI:

https://hdl.handle.net/10171/66203

DOI:

10.1038/s41408-023-00805-x

Appears in Collections:

DA - CUN - Hematología y Hemoterapia - Artículos de revista

Files in This Item: